Scientific Advisors

We rely on advice from our scientific advisors who assist us with internal triage of new applications and assessment of completed projects.


Professor Jim Owen

Professor Jim Owen is an Emeritus Professor of Molecular Medicine at UCL. His research focused on lipoprotein metabolism, cell signalling and gene-based therapeutics, encompassing liver, cardiovascular and renal diseases, parasitic infections and Alzheimer’s disease.


Dr. Keith Bragman

Dr. Keith Bragman is a senior expert for the National Institute for Health and Care Excellence (NICE) and Immediate Past President of the Faculty of Pharmaceutical Medicine of The Royal Colleges of Physicians. He is a specialist in the development of novel medicines and clinical trial methodology particularly in the fields of haematology, oncology, infectious diseases, immunology and biotechnology.


Dr. Petra Disterer

Prior to joining Rosetrees, Dr. Petra Disterer was a senior post-doctoral scientist at UCL working on oligonucleotide therapeutics. In addition to working for Rosetrees, as a scientific advisor and meeting our researchers, Petra works as a science writer for the Oligonucleotide Therapeutics Society.


Dr. Pat Goodwin

Pat has over 20 years’ experience of developing and managing Wellcome Trust funding programmes, mainly in the areas of infection and immunity, populations and public health, and molecular genetics. She represented the Wellcome Trust in partnerships with other funders, including the Malaria Genome Project, the Gates Grand Challenges, Human Heredity and Health in Africa (H3Africa), and the Public Health Centres of Excellence Initiative. She was also a Director of UK Biobank and has  served on the Councils of the Royal Society of Biology  and the Microbiology Society.



Dr Ioannis Papaioannou

Dr Ioannis Papaioannou is a lecturer in the Integrated Medical Sciences programme at UCL. He has experience in both academic and industrial translational research. His primary fields of expertise are molecular/cell biology, drug delivery and transcriptomics.